£80.0M
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
PT
Purespring Therapeutics
Purespring Therapeutics develops adeno-associated viral gene therapies for renal diseases.
London, UK—Founded 2020
£80.0MTotal raised
Purespring Therapeutics develops novel gene therapies designed to treat various forms of kidney disease by targeting specialised renal cells.
Team
JH
Julian Hanak
CEO